Syremis Therapeutics

Syremis Therapeutics is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel and Boston, Massachusetts, developing best-in-class oral small-molecule medicines for serious mental health conditions. Its neuropsychiatric pipeline is rooted in clinically validated mechanisms including muscarinic M1/M4 agonism and next-generation NMDA antagonism; lead program ST-905 is a dual M1/M4 agonist in Phase 1 for schizophrenia, with ST-901 also spun out from Clexio Biosciences. The company launched publicly in December 2025 with a $165M Series A co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet. Surfaced in the API Evangelist network as a portfolio company of GV. This company publishes no public API, developer, or event surface at this time.

Syremis Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and Mental Health.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyPharmaceuticalsMental HealthNeuroscienceDrug Discovery

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/syremis-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Syremis Therapeutics Domain Security

TLSv1.3

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: syremis-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/syremis-therapeutics.png
name: Syremis Therapeutics
description: Syremis Therapeutics is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel and Boston, Massachusetts,
  developing best-in-class oral small-molecule medicines for serious mental health conditions. Its neuropsychiatric pipeline
  is rooted in clinically validated mechanisms including muscarinic M1/M4 agonism and next-generation NMDA antagonism; lead
  program ST-905 is a dual M1/M4 agonist in Phase 1 for schizophrenia, with ST-901 also spun out from Clexio Biosciences.
  The company launched publicly in December 2025 with a $165M Series A co-led by Dexcel Pharma and Third Rock Ventures, with
  participation from Bain Capital Life Sciences, GV (Google Ventures), QVT, and Pictet. Surfaced in the API Evangelist network
  as a portfolio company of GV. This company publishes no public API, developer, or event surface at this time.
url: https://raw.githubusercontent.com/api-evangelist/syremis-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Mental Health
- Neuroscience
- Drug Discovery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/syremis-therapeutics-domain-security.yml
- type: Website
  url: https://syremis.com
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1